Breast cancer is the leading cause of cancer death among women worldwide, with about 3.2 million new cases and 1.1 million deaths expected by 2050, according to the WHO's International Agency for Research on Cancer. Up to 20% of breast cancer tumors overexpress HER2, a protein that promotes cell division and growth. Women with breast cancer that over-expresses HER2, referred to as HER2-positive breast cancer, are at greater risk for disease progression and death than women whose tumours do not over-express HER2.
The company we are profiling today is Puma Biotechnology Inc. (PBYI), the developer of breast cancer medicine Nerlynx.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com